Patents by Inventor Shino Manabe
Shino Manabe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11633499Abstract: An object of the present invention is to provide an anticancer drug capable of treating cancer by finding a target molecule specifically expressed in cancer cells and by specifically acting on the target molecule, and to provide a cancer testing method including a step of measuring the target molecule in a sample. The present invention provides an anticancer drug containing, as an active ingredient thereof, an anti-transmembrane protein 180 (TMEM-180) antibody or an antigen-binding fragment thereof. In addition, the present invention provides a cancer testing method including a step of measuring the amount of TMEM-180 in a sample collected from a subject.Type: GrantFiled: March 7, 2017Date of Patent: April 25, 2023Assignees: NATIONAL CANCER CENTER JAPAN, RIN INSTITUTE INC.Inventors: Yasuhiro Matsumura, Masahiro Yasunaga, Shinji Saijou, Shingo Hanaoka, Takahiro Anzai, Shino Manabe
-
Publication number: 20230084099Abstract: An anti-MEFLIN antibody and a pharmaceutical composition comprising the antibody is described. The pharmaceutical composition may comprise an antibody-drug conjugate (ADC) of the anti-MEFLIN antibody and a cytotoxic agent, which may be connected to each other by a linker. The pharmaceutical composition may be used in the treatment of a cancer in a subject.Type: ApplicationFiled: February 3, 2021Publication date: March 16, 2023Applicants: National University Corporation Tokai National Higher Education and Research System, Sowakai Medical FoundationInventors: Atsushi ENOMOTO, Nobutoshi ESAKI, Masahide TAKAHASHI, Yuki MIYAI, Ryota ANDO, Yukihiro SHIRAKI, Yoshihiro NISHIDA, Makoto MATSUYAMA, Shino MANABE
-
Publication number: 20230039189Abstract: A population of antibodies including homogeneous antibodies in which N-linked complex sugar chains attached to asparagine (Asn) at position 297 of CH domains of Fc regions of two heavy chains on the left and the right of each antibody are sugar chains structurally different from each other is described as well as a method of producing the population of antibodies.Type: ApplicationFiled: December 28, 2020Publication date: February 9, 2023Applicants: RIKEN, FUSHIMI PHARMACEUTICAL CO., LTD.Inventors: Shino MANABE, Yoshiki YAMAGUCHI, Shogo IWAMOTO, Takashi KINOSHITA
-
Patent number: 11311626Abstract: The present invention relates to an antibody-drug conjugate (ADC) and a composition containing the conjugate for use in treating cancer. According to the present invention, provided are an ADC of an antibody specific to insoluble fibrin and a drug in which a linker linking the antibody and the drug has a plasmin cleavage sequence, and a pharmaceutical composition containing the ADC for use in treating cancer.Type: GrantFiled: April 27, 2018Date of Patent: April 26, 2022Assignees: NATIONAL CANCER CENTER JAPAN, RIN INSTITUTE INC.Inventors: Yasuhiro Matsumura, Shino Manabe, Hirobumi Fuchigami
-
Publication number: 20200147231Abstract: The present invention relates to an antibody-drug conjugate (ADC) and a composition containing the conjugate for use in treating cancer. According to the present invention, provided are an ADC of an antibody specific to insoluble fibrin and a drug in which a linker linking the antibody and the drug has a plasmin cleavage sequence, and a pharmaceutical composition containing the ADC for use in treating cancer.Type: ApplicationFiled: April 27, 2018Publication date: May 14, 2020Inventors: Yasuhiro MATSUMURA, Shino MANABE, Hirobumi FUCHIGAMI
-
Publication number: 20190060480Abstract: An object of the present invention is to provide an anticancer drug capable of treating cancer by finding a target molecule specifically expressed in cancer cells and by specifically acting on the target molecule, and to provide a cancer testing method including a step of measuring the target molecule in a sample. The present invention provides an anticancer drug containing, as an active ingredient thereof, an anti-transmembrane protein 180 (TMEM-180) antibody or an antigen-binding fragment thereof. In addition, the present invention provides a cancer testing method including a step of measuring the amount of TMEM-180 in a sample collected from a subject.Type: ApplicationFiled: March 7, 2017Publication date: February 28, 2019Inventors: Yasuhiro MATSUMURA, Masahiro YASUNAGA, Shinji SAIJO, Shingo HANAOKA, Takahiro ANZAI, Shino MANABE
-
Patent number: 9920133Abstract: Monoclonal antibodies against human and mouse tissue factor, and fragments thereof, are disclosed, as well as pharmaceutical compositions and compositions for drug delivery containing the same. Therapeutic methods using the same are also disclosed.Type: GrantFiled: February 3, 2015Date of Patent: March 20, 2018Assignees: NATIONAL CANCER CENTER, The University of Tokyo, RIKEN, NanoCarrier Co., Ltd.Inventors: Yasuhiro Matsumura, Masahiro Yasunaga, Yoshikatsu Koga, Yoshiyuki Yamamoto, Ryuta Sato, Ryo Tsumura, Kazunori Kataoka, Nobuhiro Nishiyama, Yutaka Miura, Shino Manabe, Yasuki Kato
-
Publication number: 20160333113Abstract: Monoclonal antibodies against human and mouse tissue factor, and fragments thereof, are disclosed, as well as pharmaceutical compositions and compositions for drug delivery containing the same. Therapeutic methods using the same are also disclosed.Type: ApplicationFiled: February 3, 2015Publication date: November 17, 2016Applicants: NATIONAL CANCER CENTER, The University of Tokyo, RIKEN, NanoCarrier Co., Ltd.Inventors: Yasuhiro MATSUMURA, Masahiro YASUNAGA, Yoshikatsu KOGA, Yoshiyuki YAMAMOTO, Ryuta SATO, Ryo TSUMURA, Kazunori KATAOKA, Nobuhiro NISHIYAMA, Yutaka MIURA, Shino MANABE, Yasuki KATO
-
Patent number: 8524873Abstract: The present invention provides a compound represented by the following formula (1): wherein X1 and X2 each independently represent a hydrogen atom or a hydroxyl-protecting group; Y represents a C7-20 aralkyl group which may optionally have one or more substituents selected from a halogen atom, a lower alkyl group or a lower alkoxy group; and Z represents a halogen atom, a C1-4 alkylthio, or an arylthio group, or its corresponding sulfoxide group.Type: GrantFiled: February 28, 2007Date of Patent: September 3, 2013Assignee: RikenInventors: Shino Manabe, Yukishige Ito, Kazuyuki Ishii
-
Patent number: 8124789Abstract: This invention provides a method of producing a large amount of an ?-form or ?-form of N-pyranosyl-tryptophan having a specified structure and preparing an antibody therefrom. The method comprises a step of allowing a pyranose compound to react with a 3-pyrazyl-indole compound in the presence of a first base to obtain a 1-pyranosyl-3-pyrazyl-indole compound, and a step of treating the 1-pyranosyl-3-pyrazyl-indole compound with an acid, treating the resultant with a hydrogenation catalyst, and further treating the resultant with a second base to synthesize N-pyranosyl-tryptophan, thereby producing an antibody therefrom.Type: GrantFiled: December 8, 2008Date of Patent: February 28, 2012Assignee: RikenInventors: Shino Manabe, Yukishige Ito, Yoshito Ihara
-
Patent number: 8076299Abstract: It is an object of the present invention to provide a novel method for producing a peptide thioester. In the present invention, general peptide synthesis is performed on a solid-phase resin, carboxylic acid obtained after cutout is allowed to react with p-toluenesulfonyl isocyanate, and then the reaction product is alkylated, and is reacted with thiol. Thus, peptide thioester is simply synthesized under mild conditions.Type: GrantFiled: October 25, 2006Date of Patent: December 13, 2011Assignee: RikenInventors: Shino Manabe, Yukishige Ito, Tomoyuki Sugioka
-
Publication number: 20110287036Abstract: The present invention is intended to provide a pharmaceutical for tumor treatment that stays specifically in interstitium for a long time and exhibits an effect, and provides a complex consisting of a substance having specific binding affinity for stroma and an antitumor compound bound to the substance via a linker.Type: ApplicationFiled: November 17, 2009Publication date: November 24, 2011Applicants: RIKEN, NATIONAL CANCER CENTERInventors: Yasuhiro Matsumura, Masahiro Yasunaga, Shino Manabe
-
Publication number: 20100028329Abstract: This invention provides a method of producing a large amount of an ?-form or ?-form of N-pyranosyl-tryptophan having a specified structure and preparing an antibody therefrom. The method comprises a step of allowing a pyranose compound to react with a 3-pyrazyl-indole compound in the presence of a first base to obtain a 1-pyranosyl-3-pyrazyl-indole compound, and a step of treating the 1-pyranosyl-3-pyrazyl-indole compound with an acid, treating the resultant with a hydrogenation catalyst, and further treating the resultant with a second base to synthesize N-pyranosyl-tryptophan, thereby producing an antibody therefrom.Type: ApplicationFiled: December 8, 2008Publication date: February 4, 2010Applicant: RIKENInventors: Shino MANABE, Yukishige ITO, Yoshito IHARA
-
Publication number: 20090240034Abstract: It is an object of the present invention to provide a novel method for producing a peptide thioester. In the present invention, general peptide synthesis is performed on a solid-phase resin, carboxylic acid obtained after cutout is allowed to react with p-toluenesulfonyl isocyanate, and then the reaction product is alkylated, and is reacted with thiol. Thus, peptide thioester is simply synthesized under mild conditions.Type: ApplicationFiled: October 25, 2006Publication date: September 24, 2009Applicant: RIKENInventors: Shino Manabe, Yukishige Ito, Tomoyuki Sugioka
-
Publication number: 20070208171Abstract: The present invention provides a compound represented by the following formula (1): wherein X1 and X2 each independently represent a hydrogen atom or a hydroxyl-protecting group; Y represents a C7-20 aralkyl group which may optionally have one or more substituents selected from a halogen atom, a lower alkyl group or a lower alkoxy group; and Z represents a halogen atom, a C1-4 alkylthio, or an arylthio group, or its corresponding sulfoxide group.Type: ApplicationFiled: February 28, 2007Publication date: September 6, 2007Applicant: RIKENInventors: Shino MANABE, Yukishige ITO, Kazuyuki ISHII
-
Publication number: 20040132199Abstract: An object of the present invention is to provide a method for simply, quickly and selectively monitoring the progress of a reaction with high sensitivity in real time in the solid-phase synthesis of a sugar chain. The present invention provides a method for detecting whether or not a hydroxyl group in sugars is protected, which comprises the step of reacting the sugar having a hydroxyl group or hydroxyl group protected by a Z—CH2—CO— group wherein Z represents a halogen or —O—SO2—R, in which R represents an aliphatic or aromatic hydrocarbon group, which is immobilized to a solid phase, with a compound represented by the formula X-Y wherein X represents a residue of an azo dye compound, and Y represents a group capable of reacting with the hydroxyl group in the sugars; and/or reacting the above sugar with (p-nitrobenzyl)pyridine under basic conditions.Type: ApplicationFiled: September 30, 2003Publication date: July 8, 2004Applicant: RIKENInventors: Shino Manabe, Yukishige Ito